May 1st, 2021

The Genesis-CC Survey will conclude on 14th May 2021.

Considering our requirement to collect as many additional responses as possible, we extend a warm invitation to all healthcare professionals to partake in the survey before mid-May, 2021.

More than 2500 responses collected genesiscc post featured image April 20th, 2021

More than 2500 responses collected

The Genesis-CC Survey has achieved a total of 2500+ responses from across all parts of the world. Prof. Anker extends his thanks and gratitude to all involved associations that contributed to the survey and supported educational research.

4 additional languages available genesiscc post featured image April 1st, 2021

4 additional languages available

In order to cater to the needs of healthcare professionals, the Genesis-CC Survey has been made available in multiple languages: French, Spanish, German, and Italian. The aim is to collect as many additional responses as possible before the end of the survey.

Global Educational Evaluation Survey: 1400 responses from Japan genesiscc post featured image March 14th, 2021

Global Educational Evaluation Survey: 1400 responses from Japan

The Genesis-CC survey has achieved 1400 responses from healthcare professionals and interprofessional teams from Japan involved in recognizing, diagnosing, and managing patients with, or at risk of developing cancer cachexia. The survey is now closed for Japan and will continue for the rest of the world.

2021 Copyright, GenesisCC. Powered by Beyond
Prof. Michael Roden

Prof. Dr. Sven Francque obtained his MD at the University of Antwerp, Belgium, in 1994 and was subsequently trained in internal medicine and in gastroenterology and hepatology at the Antwerp University Hospital, Belgium and at the Department of Hepatology of the Beaujon hospital, Clichy, France. He has a long-standing interest and expertise in non-alcoholic fatty liver disease and conducted basic research focusing on the vascular changes in steatosis and their contribution to disease progression and leading to his PhD in 2011. His research unit continues to study pathophysiological mechanisms of NASH. He is also conducting clinical research and his unit is partner in several research consortia supported by the European Commission. He participates in several clinical trials in the field and was/is as scientific committee member involved in the design of several phase 2 and phase 3 trials in NAFLD. He is senior clinical researcher for the Research Fund of the Flemish government. He is currently chairman of the Department of Gastroenterology and Hepatology of the University Hospital Antwerp and professor of medicine at the Faculty of Medicine and Health Sciences of the University of Antwerp.